Relatlimab

临床试验病友交流群（点击）一、新药快讯1、HER3的抗体偶联药德帕曲妥珠单抗，治疗乳腺癌显示积极效果与EGFR和HER2属于同一个家族的HER3也有抗体偶联药，该药就是Patritumab deruxtecan，中文翻译为德帕曲妥珠单抗，根据最新公布的临床试验结果，该药对乳腺癌脑转移患者有比较好的治疗效果，21名乳腺癌脑转移患者中，23.8%的患者用药后脑部病灶缩小，疾病控制率达到了61.9%，临床获益率达到了33.3%，中位无进展生存时间达到了4个月。2、新型癌症疫苗让免疫力倍增，9名患者100%起效！最近，美国丹娜法伯癌症研究院主导的一项临床试验结果表明，针对黑色素瘤患者的个性化癌症疫苗NeoVax进行了升级，升级的版本疫苗不仅安全可行，而且激发患者的免疫系统方面更强。发布在《Cell》的研究表明，9名患者接种疫苗之后产生了积极应答，其中6名患者的抗癌免疫反应显著增强，本次临床试验还调整了疫苗注射方式，接种前后注射了PD-1抑制剂纳武利尤单抗，疫苗注射部位皮下注射了CTLA-4抑制剂伊匹木单抗。3、晚期子宫内膜癌新疗法面试，任何年龄段都有效果近日，一项重磅研究表明，一款名为多塔利单抗（Dostarlimab）的免疫药物和常规化疗搭配，可以显著延长晚期子宫内膜癌患者的肿瘤控制时间。而且不管是30岁还是70岁的病人都有效果，多塔利单抗是一种PD-1抑制剂，多塔利单抗联合化疗治疗子宫内膜癌的肿瘤控制时间比对照组多5个月，而且不管患者是不是微卫星不稳定型都适用。二、抗癌前沿1、手术之前使用免疫治疗，手术后4年8成患者不会复发最近，来自世界癌症排名第一的MD安德森癌症中心的一项研究表明，大多数晚期黑色素患者，手术之前使用双免疫疗法之后再做手术，4年之后大多数患者仍然健在，而且8成的患者没有发生复发。不过需要说明的是这两款药物分别是PD-1抑制剂纳武利尤单抗（Nivolumab），另一款药物则是LAG-3免疫药物瑞来利单抗（Relatlimab）。而且病理显示大量癌细胞在手术之前就被免疫疗法杀死，手术后95%的患者4年未复发。参加抗癌新药临床试验，请关注“癌度”微信公众号，回复数字 “1” 咨询！

MADISON, Wis.--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a clinical stage biotech company in Pittsburgh, PA. Most recently, he served as Senior Vice President of Human Immunology at Vir Biotechnology. Prior to that, he served as Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy. During his tenure at BMS and Medarex, Dr. Korman contributed to the development of three approved oncology drugs: ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and relatlimab (anti-LAG-3), as well as their combination, pioneering the use of immune checkpoint blockade in cancer therapy. Dr. Korman earned his PhD in Cellular and Developmental Biology from Harvard University and was a Whitehead Fellow at the Whitehead Institute at the Massachusetts Institute of Technology. He also served as a staff scientist at the Institut Pasteur before transitioning to the biotechnology sector. In addition to his new role on Invenra’s SAB, Dr. Korman is also the founder of Spice Biotechnologies, a company focused on developing next-generation checkpoint therapeutics. "We are thrilled to welcome Dr. Korman to our Scientific Advisory Board," said Dr. Roland Green, Co-Founder, CEO, and Chairman of Invenra. "His extensive experience in developing transformative immunotherapies aligns perfectly with Invenra's mission to collaborate with and support biotech and pharmaceutical companies of all sizes globally. We look forward to his valuable insights and contributions as we continue to empower our partners to advance innovative therapeutics." Dr. Korman joins SAB members Dr. Paul Sondel and Dr. Jonathan Davis, whose knowledge and guidance have supported Invenra’s research and development. Dr. Paul Sondel, MD, PhD, is the Reed and Carolee Walker Professor in Pediatric Oncology at the University of Wisconsin–Madison. With a distinguished career in cancer immunotherapy, Dr. Sondel has led lab, translational, and clinical research within the UW Carbone Cancer Center. His work has significantly advanced the understanding and application of immunotherapeutic strategies, including the development of FDA-approved treatments for high-risk neuroblastoma. Dr. Jonathan Davis, PhD, brings over 20 years of experience in the life sciences industry, focusing on protein and antibody engineering, as well as bispecific and multispecific antibody platform development. Prior to joining the Invenra SAB, Dr. Davis was Vice President of Innovation and Strategy for Invenra where he focused on optimization of the B-Body Platform, the development of antibody libraries, and refinements to screening methodology and throughput. Prior to Invenra, he was a Principal Scientist at Bristol-Myers Squibb, where he contributed to biologic drug design, including the development of a trispecific HIV biotherapeutic. Prior to that, he worked at EMD Serono, where he developed a variety of novel biologic drug platforms. "The collective expertise of Drs. Korman, Sondel, and Davis positions Invenra as a key collaborator and service provider, driving the discovery and development of multispecific antibody-based therapeutics in partnership with biotech and pharmaceutical companies worldwide," added Dr. Green. "Their combined knowledge and experience will be invaluable as we continue to support our partners in bringing novel treatments to patients in need." For more information about Invenra and its Scientific Advisory Board, please visit invenra.com. About Invenra Invenra Inc. is a biotechnology company specializing in next-generation multispecific antibody discovery and development. Its proprietary B-Body® platform enables the rapid generation of highly developable bispecifics and now supports both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra’s newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development.